Fibroblast activation protein-α interacts with CXCL12 to inactivate canonical Wnt signaling and regulate osteoblast differentiation.
Dong Y., Hu X., Liu W., Hao Y., Zhou J., Li X.
Animal Study, published in Stem Cells (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Stem Cells (2025)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40327708
- DOI
- 10.1093/stmcls/sxaf027
Abstract (original English)
Fibroblast activation protein-α (FAP) has been identified as an osteogenic suppressor and a potential drug target to treat osteoporosis. However, the direct role of FAP in osteoblast differentiation and the mechanism by which FAP works remains to be explored. In the current study we showed that FAP expression increased significantly during osteogenic and adipogenic differentiation of mesenchymal progenitor cells. Functional experiments revealed that FAP suppressed osteoblast differentiation and forced adipocyte formation from mesenchymal progenitor cells. Mechanistic exploration showed that FAP reduced the protein level of C-X-C motif chemokine ligand 12 (CXCL12) through directly degrading the latter. Consistently, the point mutation of the catalytic site rendered FAP fail to reduce CXCL12 protein level and fail to impact osteoblast and adipocyte differentiation. While CXCL12 activated canonical Wnt pathway, FAP inactivated canonical Wnt signaling to regulate differentiation of osteoblasts and adipocytes. CXCL12 was able to promote osteoblast differentiation while suppressing adipocyte differentiation, and attenuated the dysregulation of the differentiation tendencies induced by FAP. Taken as a whole, our study has demonstrated that FAP directly cleaves CXCL12 to inactivate canonical Wnt signaling, and therefore plays a direct role in regulating osteogenic and adipogenic differ
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.